Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 9 Years
Enrollment: 474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more

Conditions: Anemia
Interventions: BAY85-3934, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Interventions: MemoryShape® Breast Implants, MemoryGel® Breast Implants, Other Aesthetic Surgery; Device · Procedure
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3,603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 78
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more

Conditions: Hyperkalaemia
Interventions: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more

Conditions: Healthy
Interventions: NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Endothelial Dysfunction, Aging
Interventions: Aronia full spectrum - half dose, Aronia full spectrum - full dose, Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Mineral Absorption
Interventions: Liposomal multivitamin/mineral, Standard multivitamin/mineral; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Rheumatoid Arthritis
Interventions: suspension IR, CR 1, CR 2, CR 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma
Interventions: Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more

Conditions: Obesity
Interventions: NNC0519-0130 B, NNC0519-0130 C; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Actinic Keratosis
Interventions: Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 17
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 14 more

Conditions: Healthy Volunteers
Interventions: TPIP F2, TPIP F3; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Participants
Interventions: AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ABBV-154
Interventions: ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Grayslake, Illinois • Las Vegas, Nevada

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Dexmedetomidine Hydrochloride, Placebos; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Oxycodone hydrochloride tablet 30 mg, Roxicodone™ tablet 30 mg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Viral Pneumonia
Interventions: SNG001, Placebo; Drug
Lead sponsor: Synairgen Research Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Type 1 Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Insomnia, Related Distress Among Cancer Caregivers
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-I), Acupuncture, questionnaires, Diurnal Cortisol; Behavioral · Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Irvine, California • New York, New York

Conditions: Crohn Disease
Interventions: Cimzia; Biological
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more

Conditions: Type 2 Diabetes
Interventions: PATAS Trifluoroacetate, Placebo; Drug
Lead sponsor: AdipoPharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chandler, Arizona • Miami, Florida • Port Orange, Florida

Conditions: Healthy Volunteers
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Interventions: D-PLEX, Standard of Care (SoC); Drug · Other
Lead sponsor: PolyPid Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Augusta, Georgia • New Orleans, Louisiana • St Louis, Missouri + 2 more

Search by objective public record fields.

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

Memory Gel and Shape Combined Cohort

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

Effects of Aronia Berries on Vascular Endothelial Function and the Gut Microbiota in Middle-Aged/Older Adults

Pharmacokinetic Analysis of Nutrient Absorption From a Novel Liposomal Multivitamin/Mineral Formulation

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

Daily Topical Rapamycin for Vitiligo

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

BXCL501 for Agitation in Schizophrenia

Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

To Evaluate the Bioavailability of a Tablet of AZD1656

Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)